MX2023001312A - Inhibidores de quinasa y usos de los mismos. - Google Patents
Inhibidores de quinasa y usos de los mismos.Info
- Publication number
- MX2023001312A MX2023001312A MX2023001312A MX2023001312A MX2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A MX 2023001312 A MX2023001312 A MX 2023001312A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- methods
- kinase inhibitors
- compositions
- kinase
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 101100181041 Arabidopsis thaliana KINUA gene Proteins 0.000 abstract 1
- 108010055196 EphA2 Receptor Proteins 0.000 abstract 1
- -1 EphB4 Proteins 0.000 abstract 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 abstract 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 abstract 1
- 108091008794 FGF receptors Proteins 0.000 abstract 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 abstract 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 abstract 1
- 101150001535 SRC gene Proteins 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063113P | 2020-08-07 | 2020-08-07 | |
| PCT/US2021/044907 WO2022032071A1 (en) | 2020-08-07 | 2021-08-06 | Kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001312A true MX2023001312A (es) | 2023-04-12 |
Family
ID=77711412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001312A MX2023001312A (es) | 2020-08-07 | 2021-08-06 | Inhibidores de quinasa y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230303570A1 (https=) |
| EP (1) | EP4192582A1 (https=) |
| JP (1) | JP2023538521A (https=) |
| KR (1) | KR20230112605A (https=) |
| CN (1) | CN116710453A (https=) |
| AU (1) | AU2021321536A1 (https=) |
| BR (1) | BR112023002248A2 (https=) |
| CA (1) | CA3179671A1 (https=) |
| MX (1) | MX2023001312A (https=) |
| WO (1) | WO2022032071A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4577546A1 (en) * | 2022-08-25 | 2025-07-02 | Enliven Inc. | Naphthyridine compounds for inhibition of raf kinases |
| WO2024199388A1 (zh) * | 2023-03-29 | 2024-10-03 | 微境生物医药科技(上海)有限公司 | 作为myt1抑制剂的化合物 |
| WO2025064567A1 (en) * | 2023-09-19 | 2025-03-27 | Enliven Inc. | Tricyclic phenols for inhibition of raf kinases |
| WO2025152919A1 (en) * | 2024-01-15 | 2025-07-24 | Impact Therapeutics (Shanghai) , Inc. | Crystal forms of a weel inhibitor and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503802A (ja) * | 2002-04-03 | 2006-02-02 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾ縮合化合物 |
| EP2348020A1 (en) | 2009-12-23 | 2011-07-27 | Esteve Química, S.A. | Preparation process of erlotinib |
| FR2974088A1 (fr) * | 2011-04-12 | 2012-10-19 | Pf Medicament | Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux |
| RU2019102647A (ru) * | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| CN110950867A (zh) * | 2018-09-27 | 2020-04-03 | 首药控股(北京)有限公司 | 一种fgfr4激酶抑制剂及其制备方法和用途 |
-
2021
- 2021-08-06 KR KR1020237007882A patent/KR20230112605A/ko active Pending
- 2021-08-06 US US18/019,377 patent/US20230303570A1/en active Pending
- 2021-08-06 MX MX2023001312A patent/MX2023001312A/es unknown
- 2021-08-06 EP EP21769214.4A patent/EP4192582A1/en active Pending
- 2021-08-06 WO PCT/US2021/044907 patent/WO2022032071A1/en not_active Ceased
- 2021-08-06 BR BR112023002248A patent/BR112023002248A2/pt unknown
- 2021-08-06 JP JP2023507887A patent/JP2023538521A/ja active Pending
- 2021-08-06 AU AU2021321536A patent/AU2021321536A1/en active Pending
- 2021-08-06 CA CA3179671A patent/CA3179671A1/en active Pending
- 2021-08-06 CN CN202180068725.2A patent/CN116710453A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3179671A1 (en) | 2022-02-10 |
| KR20230112605A (ko) | 2023-07-27 |
| EP4192582A1 (en) | 2023-06-14 |
| JP2023538521A (ja) | 2023-09-08 |
| CN116710453A (zh) | 2023-09-05 |
| WO2022032071A1 (en) | 2022-02-10 |
| AU2021321536A1 (en) | 2023-03-09 |
| US20230303570A1 (en) | 2023-09-28 |
| BR112023002248A2 (pt) | 2023-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001312A (es) | Inhibidores de quinasa y usos de los mismos. | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| GEAP202415945A (en) | Bicyclic heterocycles as fgfr inhibitors | |
| PH12017500146B1 (en) | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof | |
| CU20150078A7 (es) | Derivados de cicloalquilo pirrolo [2, 3-d]pirimidina -4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos | |
| EA201391528A1 (ru) | Ингибиторы тирозинкиназы | |
| EA201492176A1 (ru) | Селективные ингибиторы pi3k дельта | |
| MX2016000261A (es) | Derivados de pirimidina como inhibidores de cinasa. | |
| EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| NZ718728A (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| EA201591906A1 (ru) | Производные мочевины, полезные в качестве ингибиторов киназы | |
| SA522441624B1 (ar) | مثبطات إنزيمات كيناز مستقبل عامل نمو الأرومة الليفية | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| MX2022008627A (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas. | |
| MX2025001108A (es) | Inhibidores de cinasas aminoheteroarílicos. | |
| JOP20240266A1 (ar) | مركبات تريازولو ثلاثية الحلقة كمثبطات dgk | |
| MX2023003996A (es) | Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl. | |
| MX2014011326A (es) | Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer. | |
| MX2023003995A (es) | Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl. | |
| CO2019002171A2 (es) | Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos. | |
| MX2023006434A (es) | Inhibidores de quinasa y usos de los mismos. | |
| EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 | |
| EA201792676A1 (ru) | Ингибиторы jak1 | |
| EA202091983A1 (ru) | Производные n-(фенил)-2-(фенил)пиримидин-4-карбоксамида и родственные соединения в качестве ингибиторов hpk1 для лечения рака |